RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis by Morgans, Alicia K. & Smith, Matthew R.
SAGE-Hindawi Access to Research
Journal of Osteoporosis
Volume 2011, Article ID 941310, 6 pages
doi:10.4061/2011/941310
Review Article
RANKL-Targeted Therapies:The Next Frontierin
the Treatment of Male Osteoporosis
AliciaK.MorgansandMatthew R.Smith
Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center, POB 221, Boston, MA 02114, USA
Correspondence should be addressed to Alicia K. Morgans, aliciak morgans@dfci.harvard.edu
Received 30 June 2011; Accepted 13 July 2011
Academic Editor: Pawel Szulc
Copyright © 2011 A. K. Morgans and M. R. Smith. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Male osteoporosis is an increasingly recognized problem in aging men. A common cause of male osteoporosis is hypogonadism.
Thousandsofmenwithprostatecanceraretreatedwithandrogendeprivationtherapy,atreatmentthatdramaticallyreducesserum
testosteroneandcausesseverehypogonadism.Mentreatedwithandrogendeprivationtherapyexperienceadeclineinbonemineral
density and have an increased rate of fracture. This paper describes prostate cancer survivors as a model of hypogonadal oste-
oporosis and discusses the use of RANKL-targeted therapies in osteoporosis. Denosumab, the only RANKL-targeted therapy cur-
rently available, increases bone mineral density and decreases fracture rate in men with prostate cancer. Denosumab is also as-
sociated with delayed time to ﬁrst skeletal-related event and an increase in bone metastasis-free survival in these men. It is reason-
able to investigate the use of RANKL-targeted therapy in male osteoporosis in the general population.
1. Overview
Male osteoporosis is an important issue in men’s health.
More than 2 million American men have osteoporosis and
approximately 7 million more at risk of developing the
disease. It results in an increased risk of fracture due to a
disruptedbonemicroenvironmentwithassociateddecreased
bone mineral density (BMD) and increased bone fragility.
The impact of osteoporosis on otherwise healthy men is
substantial. As men age, they generally lose BMD at a rate of
1 %p e ry e a r[ 1]. Fractures occur in one of eight men over
50 years old, with approximately 30% of all hip fractures
occurring in men [2, 3]. Mortality one year after hip fracture
for men has been estimated around 31–35%, a striking num-
ber when compared with 17–22% one-year mortality for
women of the same age [4]. In-hospital mortality alone after
a fraction is twice as high for men than for women [5, 6].
Osteoporosis has historically been classiﬁed as either pri-
mary or secondary. Primary osteoporosis is age-related or
idiopathic osteoporosis that is not clearly due to another
cause. Secondary osteoporosis results from various causes,
themostcommonofwhichinmenareglucocorticoidexcess,
heavy alcohol use, and hypogonadism. Although it can also
result from other disorders, including hyperparathyroidism,
hyperthyroidism, and malabsorptive disorders, more than
50% of male osteoporosis can be attributed to these three
causes [7]. One of the more closely studied populations with
secondary osteoporosis due to hypogonadism is prostate
cancersurvivorswhohavebeentreatedwithandrogendepri-
vation therapy (ADT). This review will focus on this unique
population as a model of hypogonadal osteoporosis to dis-
cusstheuseofRANKL-targetedtherapiesinmaleosteoporo-
sis.
2. ProstateCancer
In the United States, prostate cancer is the most common
malignancy in men and the second leading cause of cancer
death. There were over 217,730 new diagnoses of prostate
cancer in 2010, and this number continues to rise [8]. In
2010, it is estimated that there were approximately 32,050
deaths due to metastatic prostate cancer in the US [8].
Despite this, survival among all patients is 95% at 5 years,
meaning a substantial portion of the prostate cancer popula-
tion are survivors of their disease for lengthy periods of time
[8].2 Journal of Osteoporosis
3. Androgen DeprivationTherapy
Androgen deprivation therapy (ADT), by either bilateral
orchiectomies or chronic administration of a gonadotropin
releasing hormone (GnRH) agonist or antagonist, is the
mainstay of therapy for metastatic prostate cancer. The in-
tended therapeutic eﬀect of ADT is severe hypogonadism.
ADT decreases serum levels of total testosterone by more
than 95% to below 20ng/dL in most men.
ADT use has been associated with a survival advantage
in several subgroups of prostate cancer patients. For men
with high-risk locally advanced disease, the use of ADT in
addition to deﬁnitive external beam radiation therapy results
in improved disease-free and overall survival as compared to
radiation therapy alone [10]. Additionally, there is evidence
that the use of ADT after radical prostatectomy in men with
positive lymph nodes likely improves overall survival [11].
ADT can be used alone or in combination with salvage
radiation in men with a rising PSA after deﬁnitive radiation
orprostatectomyalthoughthereis not yetsuﬃcientevidence
to prove a survival beneﬁt [10].
4. Bone Loss and FracturesduringADT
Inadditiontocausingnumerousothermetabolicsideeﬀects,
ADT use is associated with a decline in BMD [12–16]. A
reduction in BMD can be seen within six to nine months of
initiating therapy, and BMD of the hip and spine continue to
decrease by approximately 2-3% per year [5, 12–14].
The incidence of fractures in men receiving ADT is also
elevated, approaching 20% after 5 years of therapy [15].
Several large population-based studies demonstrated a 21–
45% relative increase in fracture risk among men being
treated with ADT when compared to men without such
treatment [15–17] .Ar e c e n ta n a l y s i so fS E E Ra n dM e d i c a r e
data including over 50,000 men found a 19.4% rate of frac-
ture in men receiving ADT as opposed to a rate of 12.6% in
those who were not (P < 0.001) [15]. Similarly, an analysis
of 3,887 Medicare records from men with nonmetastatic
prostate cancer found ADT use associated with a relative risk
of fracture of 1.21 when compared to men who were not on
ADT (95% CI, 1.14–1.29, P < 0.01) [16].
The mechanism of ADT-related bone loss is likely par-
tially due to increased bone turnover [14]. Markers of osteo-
clastandosteoblastactivity,suchasosteocalcin,areincreased
in men receiving ADT and tend to plateau around 6 months
after initiating treatment [14]. There is also evidence that
alterations in skeletal sensitivity to parathyroid hormone
may cause increased bone turnover [18].
The eﬀects of estrogen on bone also likely contribute to
ADT-associated bone loss. ADT causes testosterone levels
to plummet, which also results in low levels of serum es-
tradiol due to the peripheral conversion of testosterone to
estrogen. Estrogen signaling through estrogen receptors on
osteoblasts and osteoclasts contributes to the regulation of
boneremodelinginmen[19].Additionally,levelsofestradiol
in healthy older men correlate with spinal bone mineral
density and are inversely associated with vertebral fracture
risk [20–22].
Recently there has been interest in using RANKL-tar-
geted therapy to reduce the incidence of osteoporosis and
fracture in men with nonmetastatic prostate cancer receiving
ADT. Like men in the general population with hypogonadal
osteoporosis, the cause of osteoporosis in these men is low
levels of testosterone. Because there is not yet primary data
with RANKL-targeted therapy in men with osteoporosis in
the general population, it is reasonable to consider extra-
polating this data to men with other forms of hypogonadal
osteoporosis for hypothesis generation and future investiga-
tion.
5. RANK-L Targeted Therapy
Bone exists in state of continuous remodeling, striking a del-
icate balance between osteoclast resorption and osteoblast
formation of new bone. The receptor activator of nuclear
factor-κB ligand (RANKL) system plays a critical role in this
balance. RANKL is a member of the tumor necrosis factor
(TNF) superfamily of proteins that is expressed by osteoclast
precursors, marrow stromal cells, and activated T-cells,
among others. It acts on its receptor, RANK, which is ex-
pressed by osteoclasts and their precursors, to stimulate
osteoclast activation, diﬀerentiation, migration, and survival
via downstream signaling through the nuclear factor kappa
B( N F κB) signaling pathway [23]. This process ultimately
results in increased osteoclast resorption of bone. A second
TNFsuperfamilymember,osteoprotegerin(OPG),functions
as the brakes in the system by counteracting the resorptive
eﬀects of the RANKL/RANK interaction. OPG, which is
produced by osteoblasts as well as many other tissues, is
a soluble decoy receptor of RANKL, binding RANKL and
inhibiting its interaction with RANK [23]. The quantity of
OPG in relation to RANK-L is believed to be the mechanism
by which bone achieves a balance between resorption and
formation [24].
Manipulation of the RANKL system has been a target
of pharmaceutical development, and denosumab is currently
the only RANKL targeted therapy available. Denosumab is
a fully human monoclonal antibody directed at RANKL.
It has a half life of more than 30 days and does not
accumulate in bone like bisphosphonates [25]. The drug
works by mimicking the eﬀects of OPG, binding RANKL,
and resulting in a reduction in osteoclast formation and
action.
Clinical trials with denosumab have demonstrated eﬃ-
cacy in fracture prevention and increased BMD in post-
menopausal women [26, 27]. A fracture prevention trial in-
cluded 7868 postmenopausal women with osteoporosis who
were randomized to receive placebo or twice yearly deno-
sumab. The denosumab group had signiﬁcantly fewer new
vertebral fractures, nonvertebral fractures, and hip fractures
than the placebo group during the 36-month study (relative
decreased risk of vertebral fractures 68%, of nonvertebral
fractures 20%, and of hip fractures 40%) [28]. Based on
this study, denosumab has been approved by the Food and
Drug Administration to treat postmenopausal women with
osteoporosis.Journal of Osteoporosis 3
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Figure 1: Mean BMD percent changes from baseline in lumbar spine and total hip sites. Results are reported as least-square means of BMD
at the lumbar spine and total hip. All values are signiﬁcantly greater in the denosumab group than the placebo group (P ≤ 0.001) [9].
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Figure 2: Incidence of new vertebral fractures during study period
in denosumab and placebo groups. Relative risk calculated for
vertebral fracture in 679 patients in the denosumab group versus
673 patients in the placebo group were 0.15 (12 months), 0.31 (24
months), and 0.38 (36 months) [9].
Denosumab has also been shown to increase BMD in
women with breast cancer who are being treated with aro-
matase inhibitors [29]. Aromatase inhibitors stop estrogen
production in peripheral tissues and cause a decline in BMD
inwomenusingthem.Arecentstudyofwomenbeingtreated
forbreastcancerwitharomataseinhibitorshasdemonstrated
that denosumab signiﬁcantly increased BMD as compared to
placebo at the lumbar spine (BMD increased by 5.5% and
7.6% at 12 and 24 months, respectively (P < 0.0001 at both
time points)).
6.De no s um abt oP r ev e ntF rac tur esd uring
ADT for Prostate Cancer
A phase 3, multicenter, double-blind, randomized controlled
trial evaluated the eﬀect of denosumab on osteoporosis and
fracture rate in men treated with ADT [9]. The trial included
men with nonmetastatic, hormone-sensitive prostate cancer
who were being treated with GnRH agonists. They were ran-
domized to receive denosumab or placebo once every 6
months with an evaluation of bone mineral density at 24 and
36 months. Similarly to prior studies with bisphosphonates
and SERMs, the primary endpoint was the change in lumbar
spine BMD. However, this trial also reported the incidence
of new vertebral fractures and the incidence of fractures
at any site as more clinically meaningful secondary end-
points.
The trial demonstrated that denosumab improved BMD
and decreased the rate of clinical fractures in men who were
treated with ADT [9] (Figures 1 and 2). At 24 months,
patients who were randomized to denosumab had an in-
creaseinBMDofthelumbarspineof5.6%ascomparedwith
a decrease in BMD of 1.0% in the placebo group (<0.001).
Signiﬁcant diﬀerences in BMD were evident in some patients
as soon as one month after treatment. At 36 months, there
was a signiﬁcant diﬀerence in the incidence of vertebral
fractures, with an incidence of 3.9% in the placebo group
versus 1.5% in the denosumab group (relative risk 0.38,
P = 0.006).
Subgroup analyses found an improvement in BMD with
denosumab at all skeletal sites and in all subgroups assessed
(Figure 3)[30].ThemostpronouncedimprovementinBMD
occurred in men with the highest markers of bone turn-
over (serum C-telopeptide and tartrate-resistant alkaline
phosphatase). Adverse events were not signiﬁcantly diﬀerent
between the two groups.
Denosumab has been recently approved in Europe for
the treatment of men receiving ADT for fracture preven-
tion based on this study. Approval of the drug in the
United States for men with nonmetastatic prostate cancer is
pending.4 Journal of Osteoporosis
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Figure 3: Forest plot of percentage change in BMD from baseline of denosumab versus placebo at lumbar spine. Vertical bar outlines the
percentage diﬀerence in BMD between denosumab and placebo at lumbar spine at 36 months [30].
7.DenosumabtoPreventSkeletal Related
EventsinMetastaticProstateCancer
Men with prostate cancer commonly develop complications
of disease related to bony metastases. Because these compli-
cations are not infrequent, and because they have a drastic
impact on patients’ quality of life, trials of bone-targeted
therapies frequently include them as study endpoints. These
bone-related complications are referred to as skeletal related
events (SREs) and are speciﬁcally deﬁned as pathologic frac-
ture, need for radiation therapy or surgery to bone, or spinal
cord compression.
Denosumab was evaluated for fracture prevention in
men with metastatic castration-resistant prostate cancer
(CRPC) in a phase III study with time to ﬁrst SRE as the
primaryendpoint.CRPCisanadvanceddiseasestatemarked
with progression despite treatment with GnRH agonists
and castrate levels of serum testosterone. This population
frequently has multiple sites of metastatic prostate cancer
involvement in the bone, and fracture is a common adverse
event.
This study randomized 1,904 men with at least one site
of bony metastasis to receive monthly zoledronic acid or
denosumab [31]. The primary endpoint was time to ﬁrst
skeletal related event, and the primary objective was the
demonstration of noninferiority of denosumab when com-
pared to zoledronic acid. Denosumab signiﬁcantly delayed
the time to ﬁrst SRE when compared with zoledronic acid
(time to ﬁrst SRE 20.7 months with denosumab versus
17.1 months with zoledronic acid; HR 0.82; P = 0.008
for superiority) [31]. Adverse events, including incidence
of osteonecrosis of the jaw, were not signiﬁcantly diﬀerent
between the two groups.
As of early 2011, denosumab has been FDA approved to
prevent SREs in patients with solid tumors and bone metas-
tases, including men with prostate cancer.
8. Denosumab to PreventBone Metastases
Almost all men with fatal prostate cancer eventually develop
metastatic disease to bone [32]. Impairing signaling in the
bone microenvironment through RANKL-targeted therapies
hasnotpreviouslybeenexploredformetastasispreventionin
prostatecancer.ArecentlycompletedphaseIIItrialevaluated
the eﬃcacy of denosumab in the prevention of bone metas-
tases in men with nonmetastatic CRPC [33]. The study ran-
domized 1432 men who were at high risk to develop bony
metastases to receive denosumab (120mg monthly) or
placebo.Theprimaryendpointwasbonemetastasis-freesur-
vival, and secondary endpoints included time to ﬁrst bone
metastasis and overall survival.
Denosumab signiﬁcantly increased bone metastasis-free
survival (time to ﬁrst occurrence of bone metastasis or on-
study death from any cause) when compared to placebo
(median bone metastasis-free survival 29.5 months and 25.2
months for denosumab and placebo, resp.) [33]. This was
a 15% decrease in risk of developing a bone metastasis for
patients treated with denosumab. Although there was no sig-
niﬁcant diﬀerence in overall survival between the groups,
denosumab increased the time to ﬁrst bone metastasis
(median time to ﬁrst bone metastasis 33.2 months with de-
nosumab versus 29.5 months with placebo).
9. Conclusions
Osteoporosis in men is a common and important health
problem. Men with prostate cancer are at particular risk forJournal of Osteoporosis 5
osteoporosis and fractures based on older age and androgen
deprivation therapy. ADT decreases bone mineral density
and increases fracture risk. In men receiving ADT for pros-
tate cancer, denosumab (60mg every 6 months) signiﬁcantly
increases bone mineral density and decreases incidence of
vertebral fractures. In men with castration-resistant prostate
cancer and bone metastases, denosumab (120mg monthly)
is superior to zoledronic acid to prevent skeletal related
events. Denosumab in the same dose and schedule also
signiﬁcantly increases bone metastasis-free survival in men
with castration-resistant nonmetastatic prostate cancer.
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